View Exam | PowerPak

1. According to the PRIMO study, which of the following individual statins showed the lowest percentage of patients with muscular symptoms?

A. Pravastatin B. Atorvastatin C. Simvastatin D. Fluvastatin

2. The LAPLACE-TIMI 57 trial assessed the effect evolocumab (AMG 145) had on lowering LDL-C levels after 12 weeks of treatment. Which of the following treatment plans had the greatest decrease in LDL-C?

A. AMG 145; 70mg given every 2 weeks B. AMG 145; 140mg given every 2 weeks C. AMG 145; 420mg given every 4 weeks D. AMG 145; 350mg given every 4 weeks

3. PCSK9 loss-of-function mutations hepatic LDL receptor expression, LDL-C levels by 15%-40%.

A. Decrease; reducing B. Increase; increasing C. Increase; reducing D. Decrease; increasing

4. For the management of patients with statin intolerance, all of the following disorders should be evaluated except:

A. Thyroid dysfunction B. Impaired renal function C. Vitamin C deficiency D. Arthritis

Maintenance is scheduled for 08/28/2024 6:00 AM EST - 08/28/2024 5:00 PM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. According to the PRIMO study, which of the following individual statins showed the lowest percentage of patients with muscular symptoms?

2. The LAPLACE-TIMI 57 trial assessed the effect evolocumab (AMG 145) had on lowering LDL-C levels after 12 weeks of treatment. Which of the following treatment plans had the greatest decrease in LDL-C?

3. PCSK9 loss-of-function mutations hepatic LDL receptor expression, LDL-C levels by 15%-40%.

4. For the management of patients with statin intolerance, all of the following disorders should be evaluated except:

« Return to Activity

Maintenance is scheduled for 08/28/2024 6:00 AM EST - 08/28/2024 5:00 PM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. According to the PRIMO study, which of the following individual statins showed the lowest percentage of patients with muscular symptoms?

2. The LAPLACE-TIMI 57 trial assessed the effect evolocumab (AMG 145) had on lowering LDL-C levels after 12 weeks of treatment. Which of the following treatment plans had the greatest decrease in LDL-C?

3. PCSK9 loss-of-function mutations ____ hepatic LDL receptor expression, ____ LDL-C levels by 15%-40%.

4. For the management of patients with statin intolerance, all of the following disorders should be evaluated except:

« Return to Activity

Customers who Purchased
this Activity also Purchased

3. PCSK9 loss-of-function mutations hepatic LDL receptor expression, LDL-C levels by 15%-40%.